ESC Universal Heart Failure Algorithm (2023 Guideline Integration Tool)

Clinical calculation support · Verify results before clinical use

Patient assessment

Complete the clinical and laboratory fields to generate a structured review.

Clinical decision aid
Adult patients only.
Use a recent ECG measurement when considering device referral.

How to interpret this tool

This tool groups LVEF as HFrEF (≤40%), HFmrEF (41–49%), or HFpEF (≥50%) and provides a structured checklist for therapy and referral discussions. HFmrEF/HFpEF diagnosis requires symptoms or signs and supporting clinical evidence; LVEF alone is not diagnostic.

The 2023 ESC focused update recommends dapagliflozin or empagliflozin for symptomatic HFmrEF and HFpEF to reduce HF hospitalisation or cardiovascular death. HFrEF therapy should generally include the four foundational medication classes when appropriate, with patient-specific sequencing and monitoring.

Device eligibility is not determined by LVEF, QRS, and LBBB alone. Confirm symptoms despite optimal therapy, rhythm, aetiology, expected survival, patient preferences, and the complete guideline criteria before referral or implantation decisions.

References and evidence base

ESC 2023 Focused Update
McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–3639.

Official article · doi:10.1093/eurheartj/ehad195

ESC 2021 Heart Failure Guideline
McDonagh TA, et al. European Heart Journal. 2021;42(36):3599–3726.

Official article · doi:10.1093/eurheartj/ehab368

Clinical disclaimer: Educational decision support only. This is not a validated prognostic score, a substitute for the full ESC guideline, or an electronic prescribing system. Verify contraindications, current drug-specific renal thresholds, monitoring requirements, local formulary, and the latest applicable guideline before acting. The 2023 label reflects the source tool; later guideline updates may supersede some recommendations.